| OS | Osteosarcoma |
| SRC | Steroid receptor co-activator |
| PD-1 | Programmed cell death 1 |
| PD-L1 | Programmed cell death ligand 1 |
| RB1 | Retinoblastoma 1 |
| TP53 | Tumor protein p53 |
| APEX1 | Apurinic/Apyrimidinic exonuclease 1 |
| BMPR2 | Bone morphogenetic protein type II receptor |
| HMGB1 | High mobility group box1 |
| RANKL | Receptor activator of nuclear factor-κB ligand |
| OPG | Osteoprotegerin |
| RTKs | Receptor tyrosine kinases |
| PDGFR | Platelet-derived growth factor receptor |
| VEGFR | Vascular endothelial growth factor receptor |
| IFNs | Interferons |
| MAP | Methotrexate, doxorubicin, and cisplatin |
| EFS | Event-free survival |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| MDP | Muramyl dipeptide |
| MTP-PE | Muramyl tripeptide phosphatidyl ethanolamine |
| IL | Interleukin |
| TNF | Tumor necrosis factor |
| PI3 | Phosphatidylinositol 3 |
| Erk | Extracellular signal regulated kinase |
| IGF-R | Insulin-Like Growth Factor Receptor |
| IGF | Insulin-Like Growth Factor |
| MAPK | Mitogen-activated protein kinase |
| PDGF/PDGFR | Platelet-Derived Growth Factor/receptors |
| RCC | Renal cell carcinoma |
| GIST | Gastrointestinal stromal tumor |
| FLT-3 | Fms-related tyrosine kinase-3 |
| HCC | Hepatocellular carcinoma |
| CML | Chronic myeloid leukemia |
| ALL | Acute lymphoblastic leukemia |
| AURK | Aurora Kinase |
| ROS | Reactive Oxygen Species |
| AMPK | 5′ Adenosine monophosphate-activated protein kinase |
| RANK/RANKL | Receptor activator of nuclear factor-κB/Ligand |
| ROCK1 | Rho-associated, coiled-coil-containing protein kinase 1 |
| NK | Natural killer |
| nab | Nanoparticle albumin-bound |
| MBC | Metastatic breast cancer |
| TS | Thymidylate synthase |
| GARFT | Glycinamide ribonucleotide formyl transferase |